The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Reversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNA
Abstract
Messenger RNAs occur within the axons of magnocellular hypothalamic neurons known to secrete oxytocin and vasopressin. In Brattleboro rats, which have a genetic mutation that renders them incapable of vasopressin expression and secretion and thus causes diabetes insipidus, injection into the hypothalamus of purified mRNAs from normal rat hypothalami or of synthetic copies of the vasopressin mRNA leads to selective uptake, retrograde transport, and expression of vasopressin exclusively in the magnocellular neurons. Temporary reversal of their diabetes insipidus (for up to 5 days) can be observed within hours of the injection. Intra-axonal mRNAs may represent an additional category of chemical signals for neurons.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Following initial studies in the early 1990s demonstrating that exogenous mRNA can direct protein expression in vivo, mRNA has emerged as a promising drug platform technology in recent years (Wolff et al, 1990; Jirikowski et al, 1992).”
From mRNA mediates passive vaccination against infectious agents, toxins, and tumors (2017) · cites this paper as Jirikowski et al, 1992
Citations
Cites
Characterization of oligonucleotide transport into living cells.
Loke, S. L., Stein, C. A., Zhang, X. H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J. S., & Neckers, L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3474 · Cited by 734
Single base deletion in the vasopressin gene is the cause of diabetes insipidus in Brattleboro rats
Schmale, H., & Richter, D. (1984) · Nature · doi:10.1038/308705a0 · Cited by 397
Parsimony Analysis in Historical Biogeography and Coevolution: Methodological and Theoretical Update
Brooks, D. R. (1990) · Systematic Zoology · doi:10.2307/2992205 · Cited by 264
Tissue-specific expression of mouse α-amylase genes
Schibler, U., Tosi, M., Pittet, A.-C., Fabiani, L., & Wellauer, P. K. (1980) · Journal of Molecular Biology · doi:10.1016/0022-2836(80)90208-9 · Cited by 187
Axonal transport of neuropeptide encoding mRNAs within the hypothalamo‐hypophyseal tract of rats.
Mohr, E., Fehr, S., & Richter, D. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07781.x · Cited by 165
Carrazana, E. J., Pasieka, K. B., & Majzoub, J. A. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.6.2267-2274.1988 · Cited by 149
mRNA coding for oxytocin is present in axons of the hypothalamo-neurohypophysial tract.
Jirikowski, G. F., Sanna, P. P., & Bloom, F. E. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7400 · Cited by 149
Self-citationMurphy, D., & Carter, D. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-7-1051 · Cited by 103
Regulation of poly(A) tail size of vasopressin mRNA.
Zingg, H. H., Lefebvre, D. L., & Almazán, G. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37914-6 · Cited by 96
Independent Regulation of Neuropeptide mRNA Level and Poly(A) Tail Length
Carter, D., & Murphy, D. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83468-8 · Cited by 89
Research works printed but not linked: 6
- CARAZANNA, E.J., MOL CELL BIOL 8: 2267 (1988).
- FRANZONI, L, RAT-BRAIN RIBONUCLEASES, ACTA PHYSIOLOGICA LATINOAMERICANA 28: 185 (1978).
- IVELL, R, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 81: 1216 (1984).
- JIRIKOWSKI, G.F., MESSENGER-RNA CODING FOR OXYTOCIN IS PRESENT IN AXONS OF THE HYPOTHALAMONEUROHYPOPHYSEAL TRACT, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 87: 7400 (1990).
- McCabe, J. J., In Situ Hybridization in Brain: 73 (1985).
- Trembleau, A., Neurocytochemical Methods: 313 (1991).
Cited by
Sorted by citations
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Tools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 762
The tangled history of mRNA vaccines
Dolgin, E. (2021) · Nature · doi:10.1038/d41586-021-02483-w · Cited by 581
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R. A., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 577
Modulation of Anxiety and Neuropeptide Y-Y1 Receptors by Antisense Oligodeoxynucleotides
Wahlestedt, C., Pich, E. M., Koob, G. F., Yee, F., & Heilig, M. A. (1993) · Science · doi:10.1126/science.8380941 · Cited by 524
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Liu, M. A. (2019) · Vaccines · doi:10.3390/vaccines7020037 · Cited by 442
mRNA vaccine: a potential therapeutic strategy
Wang, Y., Zhang, Z., Luo, J., Han, X., Wei, Y., & Wei, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01311-z · Cited by 422
Gene Regulation in the Magnocellular Hypothalamo-Neurohypophysial System
Burbach, J. P. H., Luckman, S. M., Murphy, D., & Gainer, H. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1197 · Cited by 344
mRNA vaccines for COVID-19: what, why and how
Park, J. W., Lagniton, P. N. P., Liu, Y., & Xu, R.-H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59233 · Cited by 321
Systemic delivery of factor IX messenger RNA for protein replacement therapy
Ramaswamy, S., Tonnu, N., Tachikawa, K., Limphong, P., Vega, J. B., Karmali, P. P., Chivukula, P., & Verma, I. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619653114 · Cited by 301
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Parhiz, H., Atochina‐Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 303
Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282
Engelmann, M., Wotjak, C. T., Neumann, I. D., Ludwig, M., & Landgraf, R. (1996) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(95)00059-3 · Cited by 269
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 273
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Shi, Y., Shi, M., Wáng, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 243
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., Solinís, M. Á., & del Pozo‐Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 229
Gyurko, R., Wielbo, D., & Phillips, M. I. (1993) · Regulatory Peptides · doi:10.1016/0167-0115(93)90438-e · Cited by 211
In Vitro Transcription of Long RNA Containing Modified Nucleosides
Pardi, N., Muramatsu, H., Weissman, D., & Karikó, K. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_2 · Cited by 204
Nucleic acid drugs: recent progress and future perspectives
Sun, X., Setrerrahmane, S., Li, C., Hu, J., & Xu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02035-4 · Cited by 225
Wahane, A. V., Waghmode, A., Kapphahn, A., Dhuri, K., Gupta, A., & Bahal, R. (2020) · Molecules · doi:10.3390/molecules25122866 · Cited by 202
HPLC purification of in vitro transcribed long RNA
Weissman, D., Pardi, N., Muramatsu, H., & Karikó, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_3 · Cited by 180
Carlsson, L. G., Clarke, J. C., Yen, C. Y. T., Gregoire, F. M., Albery, T., Billger, M. A., Egnell, A., Gan, L., Jennbacken, K., Johansson, E., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.003 · Cited by 186
Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide
Qiu, Y., Man, R. C. H., Liao, Q., Kung, K. L. K., Chow, M. Y. T., & Lam, J. K. W. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.026 · Cited by 178
Akabayashi, A., Wahlestedt, C., Alexander, J. T., & LEIBOWITZ, S. F. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90377-8 · Cited by 176
Current Advances in RNA Therapeutics for Human Diseases
Zogg, H., Singh, R., & Ro, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052736 · Cited by 180
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707678 · Cited by 166
“Following initial studies in the early 1990s demonstrating that exogenous mRNA can direct protein expression in vivo, mRNA has emerged as a promising drug platform technology in recent years (Wolff et al, 1990; Jirikowski et al, 1992).”
BackgroundInfluentialmRNA in the Context of Protein Replacement Therapy
Vavilis, T., Stamoula, Ε., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., & Vizirianakis, I. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010166 · Cited by 145
Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity
Tsai, S. J., Atai, N. A., Cacciottolo, M., Nice, J., Salehi, A., Guo, C., Sedgwick, A., Kanagavelu, S., & Gould, S. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101266 · Cited by 142
Nanomedicine-Based Approaches for mRNA Delivery
Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00618 · Cited by 139
mRNA as novel technology for passive immunotherapy
Schlake, T., Theß, A., Thran, M., & Jordan, I. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2935-4 · Cited by 135
The immunostimulatory nature of mRNA lipid nanoparticles
Sharma, P., Hoorn, D., Aitha, A., Breier, D., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115175 · Cited by 132
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
Wei, P.-S., Thota, N., John, G., Chang, E., Lee, S., Wang, Y., Ma, Z., Tsai, Y.-H., & Mei, K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.030 · Cited by 138
Aptamers: Cutting edge of cancer therapies
Shigdar, S. L., Schrand, B., Giangrande, P. H., & de Franciscis, V. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.010 · Cited by 130
mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
Deng, Z., Tian, Y., Song, J., An, G., & Yang, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887125 · Cited by 130
mRNA therapeutics deliver a hopeful message
Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 124
Ultrastructural Studies of Human Basophils and Mast Cells
Dvořàk, A. M. (2005) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.5r6647.2005 · Cited by 118
Optimizing Cardiac Delivery of Modified mRNA
Sultana, N., Magadum, A., Hadas, Y., Kondrat, J., Singh, N., Youssef, E., Calderon, D., Chepurko, E., Dubois, N. C., Hajjar, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.016 · Cited by 114
Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity
Liu, G., Zhu, M., Zhao, X., & Nie, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113889 · Cited by 114
Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.
Devoldere, J., Dewitte, H., De Smedt, S. C., & Remaut, K. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.009 · Cited by 112
mRNA: Fulfilling the Promise of Gene Therapy
Weissman, D., & Karikó, K. (2015) · Molecular Therapy · doi:10.1038/mt.2015.138 · Cited by 111
From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679344 · Cited by 114
Besin, G., Milton, J., Sabnis, S., Howell, R. D., Mihai, C., Burke, K. E., Benenato, K. E., Stanton, M., Smith, P., Senn, J. J., et al. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900029 · Cited by 108
Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases
Sahu, I., Haque, A. K. M. A., Weidensee, B., Weinmann, P., & Kormann, M. S. D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.019 · Cited by 104
Exosome-Based Carrier for RNA Delivery: Progress and Challenges
Lu, Y., Huang, W. C., Li, M., & Zheng, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020598 · Cited by 103
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 98
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 96
Geddes, B. J., Harding, T. C., Lightman, S. L., & Uney, J. B. (1997) · Nature Medicine · doi:10.1038/nm1297-1402 · Cited by 92
mRNA: A Novel Avenue to Antibody Therapy?
Schlake, T., Thran, M., Fiedler, K., Heidenreich, R., Petsch, B., & Fotin‐Mleczek, M. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.002 · Cited by 93
Karikó, K., Kuo, A., & Barnathan, E. S. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300930 · Cited by 89
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination
Yu, A., & Tu, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107967 · Cited by 94
Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects
Huang, T., Peng, L., Han, Y., Wang, D., He, X., Wang, J., & Ou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922301 · Cited by 87
Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery
Li, J., Wang, W., He, Y., Li, Y., Yan, E. Z., Zhang, K., Irvine, D. J., & Hammond, P. T. (2017) · ACS Nano · doi:10.1021/acsnano.6b08447 · Cited by 82
Local Gene Expression in Axons and Nerve Endings: The Glia-Neuron Unit
Giuditta, A., Chun, J. T., Eyman, M., Cefaliello, C., Bruno, A. P., & Crispino, M. (2008) · Physiological Reviews · doi:10.1152/physrev.00051.2006 · Cited by 84
mRNA vaccines: the most recent clinical applications of synthetic mRNA
Kwon, S., Kwon, M., Im, S., Lee, K., & Lee, H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01381-7 · Cited by 85
Nucleic acid therapeutics: Past, present, and future
Naeem, S., Zhang, J., Zhang, Y., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102440 · Cited by 81
Olfactory marker protein mRNA is found in axons of olfactory receptor neurons
Wensley, C., Stone, D., Baker, H. A., Kauer, J. S., Margolis, F. L., & Chikaraishi, D. M. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-07-04827.1995 · Cited by 78
Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery
Żak, M. M., & Zangi, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101675 · Cited by 75
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 81
Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
Huang, X., Ma, Y., Ma, G., & Xia, Y. (2024) · Research · doi:10.34133/research.0370 · Cited by 76
Size and Charge Characterization of Lipid Nanoparticles for mRNA Vaccines
Malburet, C., Leclercq, L., Cotte, J., Thiebaud, J., Bazin, E., Garinot, M., & Cottet, H. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04778 · Cited by 75
The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 72
N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products
Kim, K. Q., Burgute, B. D., Tzeng, S., Jing, C., Jungers, C. F., Zhang, J., Yan, L. L., Vierstra, R. D., Djuranović, S., Evans, B. S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111300 · Cited by 69
Liu, Y., Fowler, C. D., Young, L. J., Yan, Q., Insel, T. R., & Wang, Z. (2001) · The Journal of Comparative Neurology · doi:10.1002/cne.1156 · Cited by 65
RNA in the axonal domain: a new dimension in neuronal functioning?
van Minnen, J. (1994) · The Histochemical Journal · doi:10.1007/bf00160050 · Cited by 64
Hulsey, M. G., Pless, C. M., White, B. D., & Martin, R. J. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00110-w · Cited by 63
Ren, Y., Lin, L., Abdallah, M., Zhu, X., Liu, H., Fabb, S. A., Payne, T. J., Pouton, C. W., Johnston, A. P. R., & Trevaskis, N. L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113945 · Cited by 64
Monkeypox virus: An emerging epidemic
Aljabali, A. A. A., Obeid, M. A., Nusair, M. B., Hmedat, A., & Tambuwala, M. M. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105794 · Cited by 60
Adenovirus vectors enter the brain
Neve, R. L. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90174-k · Cited by 60
mRNA vaccines: a new era in vaccine development
Chandra, S., Wilson, J. C., Good, D. M., & Wei, M. Q. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.043987 · Cited by 58
Nacimiento, W., Sappok, T., Brook, G. A., T�th, L., Schoen, S. W., Noth, J., & Kreutzberg, G. W. (1995) · Acta Neuropathologica · doi:10.1007/bf00318567 · Cited by 55
mRNA vaccines in the context of cancer treatment: from concept to application
Fu, Q., Zhao, X., Hu, J., Jiao, Y., Yan, Y., Pan, X., Wang, X., & Jiao, F. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06033-6 · Cited by 59
Neuronal expression of Fos protein in the hypothalamus of rats with heart failure
Patel, K. P., Zhang, K., Kenney, M., Weiss, M. L., & Mayhan, W. G. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02186-7 · Cited by 53
mRNA therapy at the convergence of genetics and nanomedicine
Conde, J., Langer, R., & Rueff, J. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01347-w · Cited by 49
Messenger RNA-Based Therapeutics and Vaccines: What’s beyond COVID-19?
Li, D., Liu, C., Li, Y., Tenchov, R., Sasso, J. M., Zhang, D., Li, D., Zou, L., Wang, X., & Zhou, Q. A. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00047 · Cited by 50
Forenzo, C., & Larsen, J. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00439 · Cited by 48
Mohite, P. B., Yadav, V., Pandhare, R., Maitra, S., Saleh, F. M., Saleem, R. M., Al-malky, H. S., Kumarasamy, V., Subramaniyan, V., Abdel‐Daim, M. M., et al. (2024) · ACS Omega · doi:10.1021/acsomega.3c06501 · Cited by 47
Metanat, Y., Viktor, P., Amajd, A., Kaur, I., Hamed, A. M., Al-Abadi, N. K. A., Alwan, N. H., Chaitanya, M., Natrayan, L., Ghildiyal, P., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122683 · Cited by 49
Lin, C., Crowley, S. T., Uchida, S., Komaki, Y., Kataoka, K., & Itaka, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.012 · Cited by 47
Expression of the Oxytocin and Vasopressin Genes
Young, W. S. (1992) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1992.tb00201.x · Cited by 47
Conchlear inner hair cells exist transiently in the fetal Bronx waltzer (bv/bv) mouse
Whitlon, D. S., Gabel, C., & Zhang, X. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19960115)364:3 · Cited by 30
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases
Bejar, N., Tat, T. T., & Kiss, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01007-9 · Cited by 45
Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
Zhao, Y., Gan, L., Ke, D., Chen, Q., & Fu, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04553-1 · Cited by 45
The Development of mRNA Vaccines for Infectious Diseases: Recent Updates
Nitika, Wei, J., & Hui, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s341694 · Cited by 42
Optimizing Modified mRNA In Vitro Synthesis Protocol for Heart Gene Therapy
Hadas, Y., Sultana, N., Youssef, E., Sharkar, M. T. K., Kaur, K., Chepurko, E., & Zangi, L. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.07.006 · Cited by 41
Delivery of synthetic mRNAs for tissue regeneration
Steinle, H., Weber, M., Stoppelkamp, S., Große‐Berkenbusch, K., Golombek, S., Weber, M., Çanak-Ipek, T., Trenz, S.-M., Schlensak, C., & Avci‐Adali, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114007 · Cited by 42
An mRNA vaccine to prevent genital herpes
Awasthi, S., & Friedman, H. M. (2021) · Translational research · doi:10.1016/j.trsl.2021.12.006 · Cited by 41
The messenger's great message for vaccination
Pascolo, S. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1000871 · Cited by 40
Regulation of mRNA Transport and Translation in Axons
Vuppalanchi, D., Willis, D. E., & Twiss, J. L. (2009) · Results and problems in cell differentiation · doi:10.1007/400_2009_16 · Cited by 41
Trembleau, A., Morales, M., & Bloom, F. E. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00328-g · Cited by 38
Self-citationLipid-based colloidal nanoparticles for applications in targeted vaccine delivery
Khan, M. S., Appak‐Baskoy, S., Yang, C. J., Hong, J., Chae, J., Ha, H.-J., Lee, S., Tanaka, M., Choi, Y., & Choi, J. H. (2023) · Nanoscale Advances · doi:10.1039/d2na00795a · Cited by 37
Bello, M. B., Alsaadi, A., Naeem, A., Almahboub, S. A., Bosaeed, M., & Aljedani, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1475886 · Cited by 37
RNA ‐based therapies for genodermatoses
Bornert, O., Peking, P., Bremer, J., Koller, U., van den Akker, P. C., Aartsma-Rus, A. M., Pasmooij, A. M. G., Murauer, E. M., & Nyström, A. (2016) · Experimental Dermatology · doi:10.1111/exd.13141 · Cited by 37
Metadata
- Authors
- Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D., & Bloom, F. E.
- Affiliations
- Scripps Research Institute (US)
- ORCID
- Sanna, Pietro Paolo
- Venue
- Science
- Published
- 1992-02-21
- Volume
- 255
- Issue
- 5047
- Pages
- 996-998
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2082706052
- Cited by
- 282
- References
- 20
- Citations by year
- 2026: 15 · 2025: 27 · 2024: 35 · 2023: 36 · 2022: 32 · 2021: 31 · 2020: 5 · 2019: 12 · 2018: 6 · 2017: 6 · 2016: 5 · 2015: 6 · 2014: 3 · 2012: 3
- FWCI
- 17.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ns022347-08)
- National Institute of Mental Health (MH47680, P50MH047680)
- National Institute of Neurological Disorders and Stroke (NS 22347-03)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Keywords
- diabetes insipidus, Brattleboro rats, vasopressin, mRNA injection, intrahypothalamic injection, magnocellular neurons, retrograde transport, axonal mRNA transport, neuronal gene expression, oxytocin, hypothalamus
- MeSH terms
- Animals, Arginine Vasopressin, Diabetes Insipidus, Hypothalamus, Rats, Brattleboro, RNA, Messenger, Water-Electrolyte Balance, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review